Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.56 |
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 8/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | CPB1 | P15086 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3382330 | 1.00 | FOLH1 (0.56) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL3378493 | 0.94 | FOLH1 (0.49) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL3378497 | 0.94 | FOLH1 (0.49) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL3378500 | 0.94 | FOLH1 (0.49) | FOLH1GSRRNPEPMMP2MMP9 | |
| Ammonia Solution, Strong SCHEMBL17925000 | 0.92 | FOLH1 (0.47) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL18528935 | 0.83 | FOLH1 (0.43) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL29894486 | 0.83 | FOLH1 (0.59) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL29390540 | 0.83 | FOLH1 (0.59) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL48407 | 0.81 | FOLH1 (0.58) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL1272601 | 0.81 | FOLH1 (0.58) | FOLH1GSRRNPEPMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2996686-B1 | ORAL COMPOSITION COMPRISING (+)-CATECHIN | VALORE (BE) | 2019-04-03 | — | — | EP | claimed |
| EP-2120555-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | Heller, Adam (US) | 2009-11-25 | — | — | EP | claimed |
| US-20080287866-A1 | Methods and compositions for the treatment of pain | HELLER ADAM | 2008-11-20 | — | — | US | claimed |
| WO-2008094664-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | HELLER ADAM (US) | 2008-08-07 | — | — | WO | claimed |
| US-3991107-A | Haloamine transfer | NATIONAL PATENT DEVELOPMENT CORPORATION (US) | 1976-11-09 | — | — | US | claimed |
| EP-3452049-B1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12458687-B2 | Wound debridement systems | REGENICS AS (NO) | 2025-11-04 | — | — | US | disclosed |
| US-12434891-B2 | Degradable materials and packaging made from same | MONOSOL, LLC (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4596720-A2 | BACTERIAL LEADER SEQUENCES FOR PERIPLASMIC PROTEIN EXPRESSION | Pelican Technology Holdings, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-3700915-B1 | BACTERIAL LEADER SEQUENCES FOR PERIPLASMIC PROTEIN EXPRESSION | PELICAN TECH HOLDINGS INC (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-4547281-A1 | IMPROVED DOWNREGULATION OF HISTONE CYTOTOXICITY BY COMPLEX OF NEGATIVELY CHARGED POLYSACCHARIDE AND PROTEASE | Universiteit Maastricht (NL) | 2025-05-07 | — | — | EP | disclosed |
| US-20250032597-A1 | RECOMBINANT L-ASPARAGINASE | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2025-01-30 | — | — | US | disclosed |
| EP-1555531-B1 | Method for evaluating cartilage tissue degradation | SYNARC (FR) | 2007-03-07 | — | — | EP | disclosed |
| EP-1555531-A1 | Method for evaluating cartilage tissue degradation | Synarc (FR) | 2005-07-20 | — | — | EP | disclosed |
| EP-0149657-A1 | DRUG FOR TREATING AFFECTIONS RELATED TO AN UNDESIRABLE HISTAMINE LEVEL, OF THE GASTRODUODENAL MUCOSA AND ALLERGIC AFFECTIONS | CONTINENTAL PHARMA S.A. (BE) | 1985-07-31 | — | — | EP | disclosed |
| US-4507314-A | PRODUCT OF CATECHIN, LYSINE AND HYDROCHLORIC OR ASCORBIC ACID | MIDIT, SOCIETE FIDUCIAIRE (LI) | 1985-03-26 | — | — | US | disclosed |
| WO-1985000517-A1 | DRUG FOR TREATING AFFECTIONS RELATED TO AN UNDESIRABLE HISTAMINE LEVEL, OF THE GASTRODUODENAL MUCOSA AND ALLERGIC AFFECTIONS | "CONTINENTAL PHARMA" (BE) | 1985-02-14 | — | — | WO | disclosed |
| US-4285964-A | AMINE SALTS OF LYSINE OR ARGININE; BONE DISORDERS; JOINTS; CONNECTIVE TISSUE; ANTIINFLAMMATORY AGENTS; SOLUBILITY | CONTINENTAL PHARMA (BE) | 1981-08-25 | — | — | US | disclosed |
| US-3991107-A | Haloamine transfer | NATIONAL PATENT DEVELOPMENT CORPORATION (US) | 1976-11-09 | — | — | US | disclosed |
| US-3943628-A | Spoon excavator for applying chemically acting tooth decay attacking fluid | KRONMAN JOSEPH H | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287866-A1 | Methods and compositions for the treatment of pain | ACHE, S100P, P2RX3 | FOLH1 1137/4885GSR 1338/4885RNPEP 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.